- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07950878
Capturing Quality of Life and Priorities for Clinical Research in Parents and Patients With Autosomal Recessive Polycystic Kidney Disease (ARPKD PROM)
Chronic kidney disease (CKD) in childhood is a significant burden and reduces the quality of life for both children and their parents. CKD is especially burdensome when it progresses to end stage kidney disease (ESKD, previously referred to as end-stage renal disease or ESRD), placing considerable demands on a childs entire family. Although studies are available for all-cause CKD and for some disease subsets, there is no study capturing quality of life in children or adolescents specifically affected by autosomal recessive polycystic kidney disease (ARPKD). These children are often severely affected prenatally and postnatally have problems due to massive kidney enlargement, hypertension, kidney failure, and portal hypertension. They often need to receive kidney replacement therapy during childhood.
The need to include patients and their lived experience in the design of clinical trials exists for all diseases, but is implemented infrequently, especially in the field of rare diseases. The negative consequences of limited patient/parent input in clinical trial design for rare diseases has been recently highlighted by a report from the International Rare Diseases Research Consortium (IRDiRC).
Study Overview
Detailed Description
The first primary objective of this study is to assess the quality of life of children affected by autosomal recessive polycystic kidney disease (ARPKD) and their parents, using validated survey instruments.
The second primary objective is to determine priorities of patients, caregivers, and healthcare professionals regarding outcome measures in order to determine a set of core outcomes for future ARPKD-related clinical trials The secondary aim is to validate the use of existing quality of life questionnaire for this cohort of children with ARPKD and to compare their hrQoL to previously published cohorts of children with all-cause chronic kidney disease.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Jasmine Jaber
- Phone Number: 267-425-5325
- Email: jaberj2@chop.edu
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19146
- Recruiting
- Children's Hospital of Philadelphia
-
Contact:
- Jasmine Jaber
- Phone Number: 267-425-5325
- Email: jaberj2@chop.edu
-
Principal Investigator:
- Lisa Guay-Woodford, M.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Subjects should be between 0-25 years of age and have an ICD-10 diagnosis code for ARPKD in the CHOP Epic EHR.
Description
Inclusion Criteria:
- Subjects should be over 18 years of age and permanently live in the same household as the child/ young person with ARPKD.
Exclusion Criteria:
- Insufficient understanding of the questions due to intellectual capabilities or language barriers. However, translation by a professional interpreter is permissible.
Lack of written informed consent. Subjects that choose not to have their responses recorded.
Study Plan
How is the study designed?
Design Details
- Observational Models: FAMILY_BASED
- Time Perspectives: OTHER
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Patients with ARPKD and their caregivers
|
Families will be asked to fill out a series of questionnaires |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
PedsQL ESRD Questionnaire
Time Frame: 5 years
|
PedsQL ESRD Module (quality of life in children with end-stage renal disease) validated questionnaire on health-related QOL for children ≥ 24 months and adults < 25 years with renal disease. 35 questions. Ranking scale (not at all, sometimes, a lot). Items are reverse-scored and linearly transformed to a 0 to 100 scale, where higher scores indicate a better quality of life. |
5 years
|
|
SDQ (strength and difficulties questionnaire)
Time Frame: 5 years
|
validated brief emotional and behavioral screening tool. 38 questions. Ranking scale (not true, somewhat true, certainly true). Items divided into five scales of five items each, scored from 0 to 10 per scale, with four problem scales summed into a Total Difficulties score from 0 to 40. Higher scores indicate greater difficulty. |
5 years
|
|
IFS (impact on family scale)
Time Frame: 5 years
|
Caregiver burden will be captured by recording the burden on family life with the "Impact on Family Scale"(IFS). 35 questions. Ranking scale (strongly agree, agree, disagree, strongly disagree). Scored by rating each item on a 4-point Likert scale and summing the items to get a total score, where higher scores indicate a greater perceived impact of a child's health condition or disability on the family. |
5 years
|
|
ULQIE (Ulm Quality of Life Inventory for Parents of Chronically Ill Children)
Time Frame: 5 years
|
Caregiver burden will be captured by recording the burden on family life with ULQIE (Ulm Quality of Life Inventory for Parents of Chronically Ill Children). 29 questions. Ranking scale (never, rarely, sometimes, often, always). 5-point rating scale (0 = "never" to 4 = "always") based on the past 7 days, where higher scores indicate better parental quality of life. |
5 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Lisa Guay-Woodford, M.D., CHOP
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Ciliopathies
- Urogenital Diseases
- Male Urogenital Diseases
- Kidney Diseases
- Urologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Genetic Diseases, Inborn
- Congenital Abnormalities
- Abnormalities, Multiple
- Kidney Diseases, Cystic
- Polycystic Kidney Diseases
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities
- Polycystic Kidney, Autosomal Recessive
- Health Care Quality, Access, and Evaluation
- Investigative Techniques
- Epidemiologic Methods
- Data Collection
- Health Care Evaluation Mechanisms
- Quality of Health Care
- Public Health
- Environment and Public Health
- Surveys and Questionnaires
Other Study ID Numbers
- 24-022381
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.